Affiliations: 
Affiliations: 
Magnetic Resonance Imaging

130
Animal preparation 131
All imaging experiments were performed on spontaneously breathing mice under isoflurane (Isoflo®, 132 Abbot Laboratories Ltd.) anesthesia (induction 3% -maintenance 1.8%), administered in a gaseous 133 mixture of 30% O2 and 70% N2. Respiration rate, monitored with a small animal respiration pad (MR-134 compatible Small Animal Monitoring and Gating System, SA instruments, Inc.), was maintained 135 within normal physiological ranges. Rectal temperature was maintained at 37.0±0.2°C using a 136 feedback coupled warm air system (MR-compatible Small Animal Heating System, SA Instruments, 137
Inc.). To immobilize the head in a reproducible flat-skull position during the MRI experiments, mice 138 were secured in an MRI compatible mouse stereotactic device. The head was held by a nose cone -139 including tooth bar -used for anesthetic gas delivery and blunt earplugs. The tail vein was 140 cannulated with a 26-gauge needle (BD Vasculon Plus, Helsingborg, Sweden) for subsequent contrast 141 agent injection. An actively decoupled surface array (2x2) receiver coil was positioned on top of the 142 head. Homogeneous radiofrequency (RF) excitation was achieved using a proton volume resonator. 143
144
Magnetic resonance imaging: T1 weighted MRI 145
The experiments were performed on a Bruker Pharmascan 7T imaging system with horizontal bore 146 (Bruker, Ettlingen, Germany). For each animal, the following protocols were used after standard 147 spectrometer adjustments (coil tune/match, RF gain calibration, shim, scout image acquisition). To7 ensure uniform slice positioning, 2-dimensional coronal, axial and sagittal T2-weighted images were 149 acquired for each individual animal. Single slice positioning was performed in the axial plane, 150 between bregma -1.22mm and 2.18mm. Following the slice positioning, serial sets of T1-weighted 151 images were continuously obtained, before (baseline T1, pre-Gd) and every 2 minutes up to 30 152 minutes after (post-Gd) Gd-DOTA injection (0.2 mmol kg −1 ; Dotarem®; Guerbet). Gd-DOTA was 153 delivered manually and by the same experimenter. T1-weighted images were acquired using a 154 multiple inversion-recovery echo-planar imaging (IR-EPI) sequence with varying TIs: 28, 800, 1000, 155 1400, 4000, 8000ms. 
Results
176
T1 mapping
177
BBB integrity was assessed in vivo using Gd-DOTA-enhanced MRI. Body weight was determined 178 weekly to monitor general wellbeing of the mice. Overall, body weight remained constant in both 179 PDAPP and WT animals (data not shown). 180
181
In a preliminary experiment, to assess the feasibility of our approach and prior to the administration 182 of any treatment, we compared the impact of the Gd-DOTA injections on aged PDAPP and WT mice 183 (18 months old). In the cortex, a much greater T1 drop was observed in PDAPP compared to the WT 184 mice. Since amyloid is known to accumulate in the cortical vessels first, these findings suggested that 185 small BBB disruptions in old, untreated PDAPP mice, below the limit of visual detection, were greater 186 than in WT animals, even before treatment is considered (Figure 3 Table  215 1). 216
In the first study, a significant larger drop in T1 in the cortex was observed in 2 PDAPP mice treated 217 with 3D6 at week 1. After 4 weeks of treatment, one of the 2 PDAPP mice still displayed some BBB 218 impairment. No Gd-DOTA leakage was found after 12 weeks of treatment. 219
In the second study, the imaging frequency was increased to a weekly scanning protocol. After 2 220 weeks of treatment, a significantly larger drop in T1 relaxation values was observed in 1 animal. After 221 3 weeks of 3D6 treatment, the same animal and an additional animal displayed a large drop in T1 222 relaxation ( Figure 6 ). To enhance the occurrence of leakages, the dose of 3D6 was increased to 223 10mg/kg for the last 2 weeks (weeks 3 and 4). After the dose increase, three mice experienced 224 somewhat smaller ∆T1 changes of the order of 150ms -200ms. There was 1 mouse that produced an 225 event seen on the raw T1 weighted images with a ∆T1 < 100ms. 226
Due to the temporal frequency of the MRI imaging and uncertainty regarding the evolution of a BBB 227 event, it is unclear whether the smaller, minor events really have a lower magnitude peak or have 228 been imaged before or after the peak enhancement effect. In the saline-treated PDAPP group, a 229 small decrease of approximately 50ms in T1 values compared to baseline measurements (week 0) 230 was observed in the cortex at all time points. There was no treatment effect in the WT group. 231
In a third study, 16 months old PDAPP mice were treated with 3D6 and sacrificed once an event was 232 recorded. After 1 week of treatment, 1 animal showed a major event. Immediately after scanning, 233 the animal was sacrificed for histological analyses. Two additional animals with major events were 234 identified after 2 weeks of treatment. These animals were also sacrificed for histological analyses. reported in transgenic mouse models, to date only 1 publication described spontaneous appearance 275 of ARIA-H and ARIA-E in old aged transgenic mice [33] . Additionally, until now, no well-established 276 protocols were available to model treatment related ARIA. Gd-based MRI has been used in clinical as 277 well as research settings to evaluate altered BBB permeability in diseases (e.g., multiple sclerosis [34] 278 and cancer [35, 36] or injury (e.g., stroke)) [37] . After a bolus injection of Gd into the vein, the blood 279 level of Gd rises rapidly, creating a gradient across the capillary endothelial membrane. In regions 280 with relatively free capillary permeability, the contrast agent will leak across the vessel wall and 281 begins to accumulate in the perivascular interstitial fluid (e.g. muscle). In the brain, the intact BBB 282 will prevent leakage of contrast material. However, when the contrast agent leaks from the blood 283 compartment to the brain parenchyma due to BBB disruption, the altered relaxation characteristics 284 will be visible by T1 MRI. Although Gd T1 MRI has been used to probe BBB impairment in many 285 diseases, it has not been applied extensively in AD research (for review see [38] . Recently, using an 286 advanced dynamic contrast-enhanced MRI protocol, Montagne and colleagues [39] showed an age-287 dependent BBB breakdown in the hippocampus. In addition, the BBB breakdown was more 288 pronounced in MCI patients. Moreover, BBB disruptions using DCE MRI have been shown in VCI 289 patients [40] . However, so far, there is no convincing evidence of BBB disruption with this contrast-290 agent in AD, presumably due to the rapid restoration of the vascular wall. In the present study, we 291 found that T1 relaxation values decreased significantly in the meningeal and cortical midline area of 292 PDAPP mice treated with 3D6. Histological analyses showed that all the animals that displayed BBB 293 leakage visible by MRI were positive for hemosiderin by histology. Previously, it was shown that anti-294 Abeta antibody treatment in mouse models has been associated with increased incidence of vascular 295 microhemorrhages, detected by hemosiderin staining [6, 17] . Zago and colleagues [16] reported 296 histological alterations in cerebral vessels of PDAPP mice after 3D6 treatment. They showed that 297 much of the vascular Aβ clearance occurred within the first 12 weeks of treatment (86% reduction). 298
Hemosiderin deposits were detected in leptomeningeal vessels as early as 7 weeks after treatment. It 299 13 was suggested that leptomeningeal vessels containing vascular amyloid are predisposed to 300 microhemorrhages during the initial phases of A clearance by immunotherapy [16] . In the present 301 study, a subset of PDAPP mice displayed a relatively steep drop in T1 values, already after 1-2 weeks 302 of 3D6 treatment. Histological analyses showed that all the animals that displayed BBB leakage 303 visible by MRI were positive for hemosiderin by histology and these leakages seemed to occur in 304 areas with apparent reduction of Aβ plaques. Interestingly, Bapineuzumab-treated subjects with 305
ARIA-E showed greater amyloid reduction by PET imaging at week 71 [41] suggesting that BBB 306 leakage may lead to local increase of antibody concentration and higher rate of plaque clearance. 307
Interestingly, we only observed BBB leakages in a subset of 3D6-treated animals and not in WT or 308 untreated PDAPP mice. Moreover, BBB leakage events occurred early in the treatment, already 309 detectable after 1 week of immunization in a subset of animals. In addition, they seemed to be 310 transient, and thus mimicking the pattern of the ARIA events observed in a subset of clinical trial 311 patients [42] . Although the consequences of BBB disruption can lead to dysregulated molecular and 312 (n=8 PDAPP_T; n=8 PDAPP_S; n=8 WT), treatment for 12 weeks (dose 3 mg/kg/week) and study 2 527 (n=12 PDAPP_T; n=8 WT; n=12 PDAPP_S)], treatment for 5 weeks (dose 3 mg/kg/week for the first 3 528 weeks -10 mg/kg/week for the last 2 weeks). WT controls received weekly an injection with saline. 529
In study 3 (n=12 PDAPP_T), PDAPP mice at the age of 16 months were weekly injected with 3 530 mg/kg/week of 3D6 for a period of 4 weeks. In study 1, MRI was performed after 1, 4 and 12 weeks 531 of treatment. In the second and third study, MRI was performed on a weekly basis. area. Furthermore, these T1 decreases developed and recovered within the temporal resolution of 646 the study. What is not appreciated from the curves is that the increased changes in T1 preceding and 647 following the maximum T1 decline are actually different BBB events. These curves suggest that one 648 might be able to define an event threshold based solely on ∆T1. However, the situation is less 649 straightforward and more analysis is needed before a cutoff or other criteria can be determined. 650
